Zura Bio is a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Its investigational treatment, tibulizumab, is currently being evaluated in two Phase 2 trials in adults: TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa.

Zura Bio's mission is to transform the lives of those living with severe autoimmune and inflammatory conditions by aiming to deliver breakthrough treatments that offer real hope and lasting impact.

Tibulizumab is an investigational agent, meaning that its efficacy and safety have not been established by any regulatory agency worldwide.